Ac-AKY-2519 not checked
Aktis Oncology, Inc. · Cu-AKY-2519
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Prostate Cancer (2 trials), mCRPC (Metastatic Castration-resistant Prostate Cancer) (2 trials), B7H3 (2 trials), Castration Resistant Metastatic Prostate Cancer, mCRPC, NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer), ES-SCLC and 6 more
- Main trialPhase 1
- “This is a Phase 1b, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of \[64Cu\]Cu-AKY-2519 and/or \[225Ac\]Ac-AKY-2519, as well as the preliminary anti-tumor activity of \[225Ac\]Ac-AKY-2519 in participants with metastatic castration-resistant prostate cancer (mCRPC) with and without prior exposure to 177Lu-PSMA-617 (PLUVICTO™).”In the company’s words, NCT07581184 on ClinicalTrials.gov
- Other names
- Cu-AKY-2519
Other drugs for Prostate Cancer
- ApalutamideJohnson & Johnson (Janssen) · Phase 3
- 64Cu-SAR-bisPSMAClarity Pharmaceuticals Ltd · Phase 3
- Abiraterone acetateJohnson & Johnson (Janssen) · Phase 3
- 68Ga-PSMA-11Telix Pharmaceuticals (Innovations) Pty Limited · Phase 3
- EnzalutamidePfizer · Astellas · Phase 3
- MevrometostatPfizer · Phase 3
Coming up2
- Dec 2027Phase 1 trial completes · ClinicalTrials.gov
- Dec 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Dec 2027 | A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer | |
| Phase 1Recruiting | Dec 2028 | A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026